

Systems Toxicological Assessment of two Modified Risk Tobacco Products on Cardiovascular and Respiratory Effects in ApoE-/- mice - a six-month inhalation study

Blaine Phillips², Justyna Szostak¹, Emmanuel Guedj¹, Ee Tsin Wong², Marja Talikka¹, Stefan Lebrun¹, Bjoern Titz¹, Florian Martin¹, Grégory Vuillaume¹, Patrice Leroy¹, Ansgar Buettner³, Nikolai V. Ivanov¹, Patrick Vanscheeuwijck¹, Manuel C. Peitsch¹, and Julia Hoeng¹

¹ PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000 Neuchâtel, Switzerland
² PMI R&D, Philip Morris International Research Laboratories Pte. Ltd., Science Park II, Singapore
³ Histovia GmbH, Schöne Aussicht 5, D-51491 Overath, Germany


Introduction and Objectives

Cigarette smoking causes adverse health effects that may occur shortly after smoking initiation and lead to the development of cardiovascular disease (CVD), respiratory disease (e.g., chronic obstructive pulmonary disease (COPD)), and various cancers. Philip Morris International is developing Reduced Risk Products (RRP) to which adult smokers can switch and that have the potential to present less risk of harm versus continued smoking because they do not burn tobacco.


In this study, the effects of a six-month exposure to cigarette smoke (CS) or to aerosols from two RRP, the Carbon Heated Tobacco Product (CHTP) and the Tobacco Heating System (THS), were investigated in ApoE-/- mice.

CHTP 1.2 is a potential modified risk tobacco product (pM RTP) in which the tobacco plug in a specially designed stick is heated to less than 350°C using a carbon heat source. THS 2.2, a candidate MRTP, utilizes an electronically controlled heating system to heat tobacco. The operating temperature in both systems is below the combustion temperature of tobacco, resulting in generation of aerosol with significant reduction in levels of harmful and potentially harmful constituents (HPHC) compared with CS. In a systems toxicological approach combining physiological, histological, and -omics endpoints, respiratory and cardiovascular effects of these two products were assessed and compared with CS in a six-month inhalation study. In addition, the impact of cessation or switching to CHTP aerosol exposure after three months of CS exposure was evaluated.


Study Design and Endpoints




Results – Exposure and Uptake



Results – Pulmonary Inflammation




Results – Body Weight, Aortic Plaque Cholesterol and Development



Exposure to CS resulted in increased plaque formation in the aortic arch of ApoE^{-/-} mice compared with the sham exposure, starting from Month 3 and onwards (A, B). Cessation or switching to CHTP resulted in a slowing of the plaque formation, as the plaque area in these groups was trending lower than the continuous CS-exposed group in Month 4 and continuing to Month 6, where it was significantly lower. Even three months after CS exposure, the cessation and switch groups did not return to baseline (continuous fresh air) plaque area levels. There was no difference in plaque area in animals exposed to CHTP 1.2 or THS 2.2 for six months compared with the fresh air-treated animals. Statistics, ● p≤0.05, ○ p≤0.01.

Serum samples were collected during necropsy, and total cholesterol was measured (C). The CS-exposed animals had higher total cholesterol compared with the other exposure groups up to Month 4. By Month 6, there was a higher variability in the total cholesterol levels in the groups, and treatment differences were less obvious.

Results – Transcriptomics, Heart Ventricle, and Thoracic Aorta



Discussion and Conclusion

- Exposure to CS resulted in significant levels of pulmonary inflammation and decline in pulmonary function and caused adverse effects on aortic plaque formation and a dysregulation of the heart and lung transcriptome.
- Continuous exposure to two heat-not-burn tobacco products (CHTP 1.2 and THS 2.2) resulted in a very small difference in all measured parameters related to COPD and CVD when compared with fresh air-exposed animals.
- The biological responses to switching to CHTP 1.2 (after three months of CS exposure) were similar to those observed in the cessation group across the spectrum of endpoints assessed and showed a generally positive effect with respect to continuous smoke exposure.
- Differential "omics" profiles associated with CS exposure returned to sham air levels following switching to CHTP 1.2 or fresh air (cessation).
- These data collectively indicated a halting or regression of cardiovascular or emphysematous disease parameters following switching from CS exposure to CHTP 1.2 aerosol in ApoE^{-/-} mice.